EVKEEZA (evinacumab-dgnb)
ANTIHYPERLIPIDEMIC - ANGIOPOIETIN-LIKE 3 (ANGPTL3) INHIBITOR · HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Regeneron Pharmaceuticals, Inc.
Drug class
Antihyperlipidemic - Angiopoietin-like 3 (ANGPTL3) Inhibitor
The drug class antihyperlipidemic angiopoietin-like 3 (ANGPTL3) inhibitors consists of targeted biologic therapies designed to treat severe dyslipidemias by binding to and neutralizing the circulating hepatic protein ANGPTL3. Read more about Antihyperlipidemic - Angiopoietin-like 3 (ANGPTL3) Inhibitor
1 drugs in this class 1 manufacturers
Drugs in Antihyperlipidemic - Angiopoietin-like 3 (ANGPTL3) Inhibitor
Filter & compare in the drug finder →
Opens the drug finder with Antihyperlipidemic - Angiopoietin-like 3 (ANGPTL3) Inhibitor preselected. Add indication or manufacturer filters there.
The drug class antihyperlipidemic angiopoietin-like 3 (ANGPTL3) inhibitors consists of targeted biologic therapies designed to treat severe dyslipidemias by binding to and neutralizing the circulating hepatic protein ANGPTL3.
Inhibiting ANGPTL3 removes its natural suppression of lipoprotein lipase and endothelial lipase, which promotes the clearance of very low-density lipoprotein precursors and substantially reduces circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides through a low-density lipoprotein receptor-independent mechanism.
In clinical practice, this class is primarily used as an adjunct to diet and other lipid-lowering therapies for patients with homozygous familial hypercholesterolemia, a rare genetic disorder marked by refractory elevations in LDL-C and extreme cardiovascular risk.
-
nih.gov
The drug class antihyperlipidemic angiopoietin-like 3 (ANGPTL3) inhibitors consists of targeted biologic therapies designed to treat severe dyslipidemias by binding to and neutralizing the circulating hepatic protein ANGPTL3 Inhibiting ANGPTL3 removes its natural suppression of lipoprotein lipase and endothelial lipase, which promotes the clearance of very low-density lipoprotein precursors and substantially reduces circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides throug...
-
nih.gov
The drug class antihyperlipidemic angiopoietin-like 3 (ANGPTL3) inhibitors consists of targeted biologic therapies designed to treat severe dyslipidemias by binding to and neutralizing the circulating hepatic protein ANGPTL3 In clinical practice, this class is primarily used as an adjunct to diet and other lipid-lowering therapies for patients with homozygous familial hypercholesterolemia, a rare genetic disorder marked by refractory elevations in LDL-C and extreme cardiovascular risk
-
fda.gov
Inhibiting ANGPTL3 removes its natural suppression of lipoprotein lipase and endothelial lipase, which promotes the clearance of very low-density lipoprotein precursors and substantially reduces circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides through a low-density lipoprotein receptor-independent mechanism
-
nih.gov
Inhibiting ANGPTL3 removes its natural suppression of lipoprotein lipase and endothelial lipase, which promotes the clearance of very low-density lipoprotein precursors and substantially reduces circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides through a low-density lipoprotein receptor-independent mechanism
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.